Alvotech Dividendos y recompras
Dividendo controles de criterios 0/6
Alvotech no tiene historial de pago de dividendo.
Información clave
n/a
Rentabilidad por dividendo
-8.0%
Rendimiento de la recompra
| Rendimiento total para el accionista | -8.0% |
| Rendimiento futuro de los dividendos | 0% |
| Crecimiento de los dividendos | n/a |
| Próxima fecha de pago de dividendos | n/a |
| Fecha ex dividendo | n/a |
| Dividendo por acción | n/a |
| Ratio de pago | n/a |
Últimas actualizaciones de dividendos y recompras
Recent updates
ALVO: Biosimilar Pipeline And Partnerships Will Shape Future Upside Potential
Analysts have reduced their price targets on Alvotech, with the consolidated fair value estimate moving from $5.00 to $4.00 as they factor in more moderate revenue growth, lower profit margin assumptions, a higher discount rate, and a higher future P/E multiple. Analyst Commentary Bearish analysts are aligning around a lower fair value for Alvotech, with recent price target revisions pointing to a more cautious stance on the stock.Alvotech: Improving Fundamentals Signal A Potential Bottom For This Biosimilar Player
Apr 10
ALVO: Executing Biosimilar Pipeline And 2026 Revenue Plan Will Unlock Upside
Analysts have reset their view on Alvotech, trimming the average price target from about $22.17 to $14.00 as they factor in updated assumptions for growth, profitability and a higher future P/E, in line with recent target cuts from Deutsche Bank, Barclays and UBS. Analyst Commentary Recent Street research around the reset in the average price target to about $14.00 centers on how quickly Alvotech can execute on its pipeline and translate that into sustainable profitability, as well as what P/E multiple is appropriate given current visibility.
ALVO: Biosimilar Pipeline Progress And Patent Resolutions Will Support Future Upside
Analysts have adjusted their price target for Alvotech to $64.74 per share. This reflects updated assumptions on discount rate, revenue growth, profit margins and future P/E, while keeping the overall valuation level unchanged.ALVO: Patent Resolution And Biosimilar Progress Will Support Future Upside
Analysts have updated their price target on Alvotech to $64.74 from $82.94, reflecting revised assumptions around fair value, discount rate, revenue growth, profit margin, and future P/E multiples. What's in the News Alvotech reported positive top line pharmacokinetic results for AVT80, its biosimilar candidate to Entyvio (vedolizumab), with the PK study meeting all primary endpoints in healthy adults, while biosimilarity has not yet been established by regulators.ALVO: Biosimilar Progress And New Partnerships Will Shape Balanced Risk Outlook
Analysts have raised their price target on Alvotech to $5.00. This change is supported by slightly higher assumptions for revenue growth, profit margin and future P/E.ALVO: Rebased UBS View And Patent Resolution Will Support Future Upside
Narrative Update on Alvotech Analysts have reduced their price expectations for Alvotech, with one recent update moving a target to US$10 from US$13, along with lower fair value estimates and more conservative assumptions for revenue growth, profit margins, and future P/E multiples. Analyst Commentary Even with lower headline price targets, some bullish analysts still see room for upside in Alvotech.ALVO: FDA Letters And Facility Remediation Will Guide Balanced Risk Outlook
Narrative Update on Alvotech The updated analyst price targets for Alvotech, which now cluster around US$8 to US$10 compared with prior views near US$13 to US$14, reflect analysts factoring in recent FDA complete response letters tied to inspection findings at the Reykjavik facility, while still recognizing the unchanged US$5 fair value estimate and broadly similar growth and margin assumptions in the model. Analyst Commentary Recent Street research on Alvotech points to a more cautious tone, with price targets now centered in the US$8 to US$10 range and at least one rating move to Hold after the complete response letter for AVT05 and related inspection findings at the Reykjavik facility.ALVO: FDA Setbacks And Manufacturing Fixes Will Shape Balanced Risk Profile
Analysts have trimmed their fair value estimate for Alvotech from US$14.00 to US$5.00. This reflects lower price targets on the stock after recent FDA-related setbacks and manufacturing inspection concerns highlighted in recent research updates.ALVO: Resolution Of FDA Inspection Issues Will Unlock Biosimilar Launch Upside
Analysts have reduced their average price target for Alvotech from about $26.40 to roughly $22.17 per share, citing FDA inspection related uncertainties around key biosimilar launches, as well as a series of recent target cuts and rating downgrades, as justification for a lower, though still constructive, valuation framework. Analyst Commentary Recent Street research reflects a more cautious stance on Alvotech, with several firms cutting price targets and one moving to the sidelines following regulatory setbacks tied to the company’s biosimilar pipeline.ALVO: Regulatory Resolution Of Manufacturing Issues Will Restore Confidence And Future Upside
Analysts have trimmed their price targets on Alvotech, with cuts of roughly $3 to $6 per share. The reductions reflect increased perceived regulatory risk after recent FDA feedback on key biosimilar programs.Statutory Earnings May Not Be The Best Way To Understand Alvotech's (NASDAQ:ALVO) True Position
Nov 20
ALVO: Regulatory Progress Will Drive Renewed Confidence Amid Recent Downgrade
Alvotech's fair value price target saw a significant increase from $16.10 to $26.40, as analysts revised their outlook based on recent research reports and updated fundamentals. Analyst Commentary Recent analyst reports on Alvotech reflect a mix of optimism about the company's long-term potential and caution regarding recent regulatory and operational setbacks.Alvotech's (NASDAQ:ALVO) 31% Dip In Price Shows Sentiment Is Matching Revenues
Nov 09Analysts Just Slashed Their Alvotech (NASDAQ:ALVO) EPS Numbers
Nov 06ALVO: Facility Improvements Will Drive Recovery Despite Recent Regulatory Setbacks
Alvotech’s analyst price target has decreased from $17.50 to $16.10 per share. This change reflects analyst concerns over FDA feedback and the resulting downgrades after a recent inspection of the company’s manufacturing facility.Alvotech (NASDAQ:ALVO) Held Back By Insufficient Growth Even After Shares Climb 29%
May 25Alvotech's (NASDAQ:ALVO) Promising Earnings May Rest On Soft Foundations
May 15Biosimilar Pipeline And R&D Capability Will Open New Markets
Upcoming biosimilar launches and strategic manufacturing expansions might drive substantial revenue and margin growth, leveraging lost biologic patents.Benign Growth For Alvotech (NASDAQ:ALVO) Underpins Stock's 25% Plummet
Apr 08Alvotech's Position In The Coming Biosimilar Gold Rush
Nov 21Alvotech: Steady Progress Offers A Good Chance Of Upside
Aug 26Bullish: Analysts Just Made A Huge Upgrade To Their Alvotech (NASDAQ:ALVO) Forecasts
May 28Alvotech: Consider Buying As Positive Q1 Earnings Release Likely
Apr 25Alvotech (NASDAQ:ALVO) Shares May Have Slumped 28% But Getting In Cheap Is Still Unlikely
Apr 03Alvotech (NASDAQ:ALVO) Just Reported Yearly Earnings: Have Analysts Changed Their Mind On The Stock?
Mar 24Estabilidad y crecimiento de los pagos
Obteniendo datos sobre dividendos
Dividendo estable: No hay datos suficientes para determinar si los dividendos por acción de ALVO han sido estables en el pasado.
Dividendo creciente: Datos insuficientes para determinar si los pagos de dividendos de ALVO han aumentado.
Rentabilidad por dividendo vs. Mercado
| Rentabilidad por dividendo de Alvotech vs. Mercado |
|---|
| Segmento | Rentabilidad por dividendo |
|---|---|
| Empresa (ALVO) | n/a |
| Suelo de mercado 25% (US) | 1.4% |
| Techo de mercado 25% (US) | 4.2% |
| Media de la industria (Biotechs) | 2.6% |
| Analista de previsiones (ALVO) (hasta 3 años) | 0% |
Dividendo destacado: No es posible evaluar la rentabilidad por dividendo de ALVO en comparación con el 25% inferior de los pagadores de dividendos, ya que la empresa no ha comunicado ningún pago reciente.
Alto dividendo: No es posible evaluar la rentabilidad por dividendo de ALVO en comparación con el 25% de los principales pagadores de dividendos, ya que la empresa no ha comunicado ningún pago reciente.
Pago de beneficios a los accionistas
Cobertura de los beneficios: No hay datos suficientes para calcular el ratio de pago de ALVO para determinar si sus pagos de dividendos están cubiertos por los beneficios.
Pago en efectivo a los accionistas
Cobertura de flujo de caja: No es posible calcular la sostenibilidad de los dividendos, ya que ALVO no ha comunicado ningún pago.
Descubre empresas que pagan buenos dividendos
Análisis de la empresa y estado de los datos financieros
| Datos | Última actualización (huso horario UTC) |
|---|---|
| Análisis de la empresa | 2026/04/30 13:06 |
| Precio de las acciones al final del día | 2026/04/29 00:00 |
| Beneficios | 2025/12/31 |
| Ingresos anuales | 2025/12/31 |
Fuentes de datos
Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.
| Paquete | Datos | Marco temporal | Ejemplo Fuente EE.UU. * |
|---|---|---|---|
| Finanzas de la empresa | 10 años |
| |
| Estimaciones del consenso de analistas | +3 años |
|
|
| Precios de mercado | 30 años |
| |
| Propiedad | 10 años |
| |
| Gestión | 10 años |
| |
| Principales avances | 10 años |
|
* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.
A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.
Modelo de análisis y copo de nieve
Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.
Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.
Métricas industriales y sectoriales
Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.
Fuentes analistas
Alvotech está cubierta por 9 analistas. 5 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.
| Analista | Institución |
|---|---|
| Glen Santangelo | Barclays |
| Andrew Baum | Citigroup Inc |
| Peter Verdult | Citigroup Inc |